A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019 by Monica Peravali, MD, Ishani Joshi, BA, Jaeil Ahn, PhD, Chul Kim, MD, MPH

Get full text

EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report by Xinyu von Buttlar, MD, MS, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH

Get full text

Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors by Samuel A. Kareff, MD, MPH, Suraj Samtani, MD, Mauricio Burotto, MD, MSc, Vinay Prasad, MD, MPH, Chul Kim, MD, MPH

Get full text

Osimertinib and Capmatinib Combination Therapy to Overcome MET Y1003N-Mediated Resistance in EGFR-Mutant NSCLC: A Case Report by Molly Wilgucki, DO, Vincent Yeung, MD, Grace Ho, MD, Gabriela L. Bravo Montenegro, MD, Greg Jones, Joshua E. Reuss, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH

Get full text

Remarkable Intracranial Response to Sotorasib in a Patient With KRASG12C-Mutated Lung Adenocarcinoma and Untreated Brain Metastases: A Case Report by Justin Yeh, MD, Jennifer A. Marks, MD, Ali H. Alzeer, MD, Emily A. Sloan, MD, PhD, Reshma Varghese, MD, Nitika Paudel, MD, PhD, Joshua E. Reuss, MD, Peter J. Bergquist, MD, Stephen V. Liu, MD, Chul Kim, MD, MPH

Get full text